Resverlogix Corp. is a late-stage clinical biotechnology company focused on developing therapeutics for chronic illnesses, primarily through its lead drug, apabetalone. The company faces significant financial concerns, highlighted by a negative return on assets of -12.1% and extremely low liquidity ratios (current ratio of 0.04 and quick ratio of 0.02), indicating potential cash flow issues. Additionally, the stock price of $0.09 reflects a low market cap of $29.26M, suggesting investor skepticism about its future prospects despite its innovative pipeline.
Loading financial metrics...
Company has $64K in cash but burned $617K last quarter. At this burn rate, only 0.1 quarters of runway remain without additional financing.
Company posted a loss of $-12.0M over the last year, representing Infinity% of revenue.
Debt of $19.5M is 304.8x the company's cash position of $64K.
Operating cash flow has been negative for 3 consecutive quarters, burning $2.5M over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (September 30, 2025)